SuperworthIN8BIO INAB
- Market cap
- $10.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- −141.0%
IN8BIO's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $3.8M−11% | $4.5M+15% | $4.9M+12% | $5.2M+25% | $3.3M−13% | $3.6M−21% | $3M−39% | $2.5M−52% | $2.1M−36% | $2.6M−26% | $2.6M−12% | $2.5M+0% |
| SG&A | $3.4M+8% | $3.1M−21% | $3.7M+8% | $3.5M−1% | $2.7M−19% | $2.6M−15% | $2.7M−28% | $2.7M−23% | $1.9M−32% | $2.4M−9% | $2.7M−1% | $2.4M−10% |
| −$7.2M−3% | −$7.6M−3% | −$8.6M+14% | −$8.6M+12% | −$7.1M−1% | −$6.2M−19% | −$5.5M−35% | −$5.1M−41% | −$3.9M−46% | −$4.9M−20% | −$5.1M−8% | −$4.8M−6% | |
| Net income | −$7.2M−3% | −$7.6M−3% | −$8.6M+14% | −$8.6M+12% | −$7.1M−1% | −$6.2M−19% | −$5.5M−35% | −$5.1M−41% | −$3.9M−46% | −$4.9M−20% | −$5.1M−8% | −$4.8M−6% |
| −$6.90−32% | −$6.60−31% | −$6.00−33% | −$5.51−32% | −$4.49−35% | −$2.38−64% | −$2.16−64% | −$1.24−78% | −$0.85−81% | −$0.70−71% | −$0.26−88% | −$0.25−80% | |
| 1.1M+46% | 1.2M+41% | 1.4M+75% | 1.6M+65% | 1.6M+50% | 2.6M+125% | 2.6M+79% | 4.1M+163% | 4.5M+188% | 7.1M+173% | 19.5M+656% | 19.5M+373% |
R&D: Q1 FY20: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20 and Q1 FY21: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest IN8BIO's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| INABIN8BIO | $10.4M | n/m | n/a | n/m | n/m | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $64.6M | 13.6× | 14.8× | 1.1× | +6% | 4.9% |
More on IN8BIO
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .